Here are the S-1 registration statements from Parabilis Medicines, Inc. (PBLS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow PBLS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PBLS filings page.
Parabilis Medicines, Inc. is launching an initial public offering of 33,333,334 shares of voting common stock. The estimated price range is $17.00 to $19.00 per share, and underwriters have a 5,000,000-share overallotment option. A concurrent Regeneron private placement is expected to add about $75.0 million at 90% of the IPO price.
Based on an assumed $18.00 price, Parabilis projects approximately $553.1 million in net IPO proceeds plus $75.0 million from the private placement, boosting pro forma cash to about $957.1 million. The company, a clinical-stage oncology-focused biopharma built around its Helicon peptide platform, plans to fund late-stage development of lead candidate zolucatetide and advance a broader pipeline, while remaining an emerging growth and smaller reporting company with considerable operating losses.
Parabilis Medicines, Inc. is launching an initial public offering of 25,000,000 shares of voting common stock, with an estimated price range of $17.00 to $19.00 per share, and a planned Nasdaq Global Market listing under the symbol PBLS.
The company is a clinical-stage biopharmaceutical developer of “Helicons,” stabilized helical peptides designed to drug historically undruggable intracellular protein targets. Its lead candidate, zolucatetide, targets the Wnt/β‑catenin pathway and has shown tumor reductions in desmoid tumors and activity across multiple Wnt/β‑catenin–driven cancers.
Parabilis estimates $413.6 million in net IPO proceeds (at a midpoint price of $18.00), plus a $75.0 million concurrent private placement to Regeneron at 90% of the IPO price. As of March 31, 2026, it held $329.0 million in cash and cash equivalents and reported a 2025 net loss of $145.9 million, reflecting heavy R&D investment and no product revenue.
Parabilis Medicines, Inc. filed Amendment No. 1 to its registration statement on Form S-1. The amendment is described as being filed solely to add and update certain exhibits, including equity incentive plans, a stock option and incentive plan, an employee stock purchase plan, key licensing and loan agreements, and executive and director compensation arrangements. The company states that the remainder of the registration statement is unchanged and has been omitted from this amendment.
Parabilis Medicines, Inc. is a clinical-stage biopharmaceutical company planning an initial public offering of voting common stock on the Nasdaq Global Market under the symbol PBLS, alongside a concurrent $75.0 million private placement to Regeneron at 90% of the IPO price.
The company is developing Helicons, stabilized helical peptides designed to drug historically undruggable intracellular targets. Lead candidate zolucatetide targets the Wnt/β‑catenin pathway and has treated over 150 patients. In desmoid tumors, all 25 response‑evaluable patients showed tumor reductions and 74% of 19 patients with at least two post‑baseline scans achieved an objective response.
Parabilis is also studying zolucatetide in familial adenomatous polyposis, hepatocellular carcinoma, additional rare Wnt/β‑catenin–driven tumors, and colorectal cancer, and advancing ERG and ARON degraders for prostate cancer. The company reported a net loss of $145.9 million in 2025 and had cash and cash equivalents of $329.0 million and an accumulated deficit of $586.8 million as of March 31, 2026. Proceeds from the IPO and private placement, plus a $50.0 million upfront Regeneron payment, are earmarked mainly for zolucatetide clinical programs, pipeline advancement, platform development, and general corporate purposes.